Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søg Study Connect


A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants With Alpha (α)-Thalassemia - CA056-015

Opdateret: 23 februar, 2024   |

Udskriftsvenligt sammendrag

Udskriv denne side og forsøgsvejledningen som en hjælp til at tale med din læge.
Brug vejledningen til forsøgsdeltagere for at finde rundt i processen for deltagelse i et klinisk forsøg. Forstå de vigtigste faktorer, der skal overvejes, før du beslutter dig, og find spørgsmål, du kan stille dit sundhedsteam.


  • Phase 2


  • Køn

  • 12+


  • 4


  • Recruiting


Experimental: Non-transfusion Dependent (NTD): Luspatercept + BSC
Biological: Luspatercept
Placebo Comparator: NTD: Placebo + BSC
Drug: Placebo
Placebo Comparator: TD: Placebo + BSC
Drug: Placebo
Experimental: Transfusion Dependent (TD): Luspatercept + Best supportive care (BSC)
Biological: Luspatercept

Primære egnethedskriterier

Key Inclusion Criteria: - Participant has documented diagnosis of α-thalassemia hemoglobin H (HbH) disease (electrophoresis⎯ or high-performance liquid chromatography [HPLC]⎯based methods for Hb variant analyses are accepted), with or without transfusion dependence; compounded combination with β-thalassemia is allowed if at least 1 non-mutated β-chain gene is present. TD: i) TD participant: (1) ≥ 6 RBC units during the 24 weeks prior to randomization; and (2) No transfusion-free period for > 56 days during the 24 weeks prior to randomization; ii) NTD participant: (1) < 6 Red blood cell (RBC) units during the 24 weeks prior to randomization; and (2) RBC transfusion-free during at least 8 weeks prior to randomization; and (3) Mean baseline Hb ≤ 10 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to randomization; hemoglobin values within 21 days post-transfusion will be excluded. - Participant has Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. - Investigators shall counsel women of childbearing potential (WOCBP), and male participants who are sexually active with WOCBP, on the importance of pregnancy prevention, the implications of an unexpected pregnancy, and the potential of fetal toxicity occurring due to transmission of study intervention, present in seminal fluid, to a developing fetus, even if the participant has undergone a successful vasectomy or if the partner is pregnant. Key Exclusion Criteria: - Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study. - Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study - History of deep venous thrombosis (DVT) or stroke requiring medical intervention ≤ 24 weeks prior to randomization - Diagnosis of α-thalassemia Trait, Hb Bart hydrops, ATRx α-thalassemia, hemoglobin S/β-thalassemia, myelodysplasia subtype anemia, or with HbE homozygous beta gene mutation. - Anemia related to nutritional deficiency, anemia of chronic disease, autoimmune hemolytic anemia, or any other hemolytic anemias (for example, severe G6PD deficiency, pyruvate kinase deficiency, etc.). - Bleeding disorders manifested by frequent bleeding episodes (e.g., menorrhagia, epistaxis, clotting disorders). - Undergone episodes of hemolysis not related to alpha-thalassemia, for example, after use of hemolysis-predisposing drugs (for example, antimalarial, nonsteroidal anti-inflammatory drug [NSAID]), within the 8 weeks prior to randomization. - Prior exposure to gene therapy to treat α-thalassemia. - Use of an erythropoiesis-stimulating agent (ESA) ≤ 24 weeks prior to randomization. Note: Other protocol-defined inclusion/exclusion criteria apply.

Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information